NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA). Investors who purchased Atara securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATRA.

SHOEMAKERSVILLE, Pa., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Hydrofarm Holdings Group, Inc. (Nasdaq: HYFM) (“Hydrofarm” or the “Company”) today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's common stock, par value $0.0001, which will be effective at 5:00 pm Eastern Time on February 12, 2025. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on February 13, 2025, under the Company's existing trading symbol “HYFM.”

SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Dan Kirby will join the Company's executive leadership team in the newly created role of Chief Commercial Officer, effective today.

Glass Lewis Finds Matthews Has "Persistently Deteriorated and Consistently Underperformed During Substantially All Measurement Periods, Including During the Fullness of Mr. Bartolacci's Tenure as CEO" Asserts Barington "Has Offered Investors a Reasonable, Credible and Incremental Slate of Candidates" and a "More Promising Roadmap" for the Company Recommends Shareholders Vote "WITHHOLD" on Matthews' Nominees Terry L.

Global Systemwide sales* were over $130 billion for the full year, with full year growth of more than $1 billion (more than $2 billion in constant currencies) Systemwide sales to loyalty members were approximately $30 billion for the full year and approximately $8 billion for the quarter across 60 loyalty markets, with full year growth of 30% over prior year 90-day active loyalty users were over 175 million across 60 loyalty markets as of year-end, with growth of approximately 15% over prior year CHICAGO , Feb. 10, 2025 /PRNewswire/ -- McDonald's Corporation today announced results for the fourth quarter and …

The Keynote Titled ״Is the future of video processing destined for GPU?״ Describes First Hand The Evolution of Video Encoding in the Past Decades Herzliya Israel, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Beamr Imaging Ltd.

Streamlining the Referral Process to Enhance Efficiency and Patient Experience SOMERSET, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO, CCLDP), a leader in healthcare technology and AI-driven solutions, is proud to announce the launch of its new advanced referral module.

Gross Profit Increased 23.5% from the Previous Year to $7.7 million Gross Margins Increased to 18.5%, up from 15.0% the Previous Year Revenue Increased 0.3% Year-Over-Year to $41.8 Million LOS ANGELES , Feb. 10, 2025 /PRNewswire/ -- Ispire Technology Inc. ( NASDAQ: ISPR ) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported results for the fiscal second quarter 2025, which ended on December 31, 2024. Fiscal Second Quarter 2025 Financial Results Revenue of $41.8 million, compared to $41.7 million for the fiscal second quarter of 2024.

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced today that Donald Munoz is joining the Company as chief financial officer (CFO), reporting to Greg Kunst, chief executive officer (CEO). “We are delighted to welcome Don to our executive team,” said Greg Kunst, Aurion's CEO. “Don's track record of strategic and operational financial leadership, coupled.

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Caribou securities between July 14, 2023 and July 16, 2024, both dates inclusive (the "Class Period").

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Nextracker Inc. ("Nextracker" or "the Company") (NASDAQ: NXT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Nextracker securities between February 1, 2024 and August 1, 2024, both dates inclusive (the "Class Period").

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Capri Holdings Limited ("Capri" or "the Company") (NYSE:CPRI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Capri securities between August 10, 2023 and October 24, 2024, both dates inclusive (the "Class Period").

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Pacira securities between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period").

SAN FRANCISCO , Feb. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells (Tregs).

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Enphase Energy, Inc. ("Enphase" or "the Company") (NASDAQ:ENPH) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Enphase securities between April 25, 2023 and October 22, 2024, both dates inclusive (the "Class Period").

WALTHAM, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc Elia, Chairman of the Invivyd Board of Directors, will be presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT Hosting 1x1 meetings on Tuesday, February 11th and Wednesday, February 12th TD Cowen 45th Annual Health Care Conference in Boston, MA Fireside chat on Tuesday, March 4th at 10:30 a.m. Eastern Tim.

PetMed Express stock could surge or sink after this week's quarterly earnings release, but don't read too much into this near-term event. A disappointing earnings release won't necessarily shatter the bull case, and could, in fact, push this stock back down to "back up the truck" price levels. Conversely, even if PETS rallies on strong results, this may not capture all of the potential long-term upside.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Announces Positive Topline Results for Breyanzi in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma.